IngredientsHericenones are a structurally unique class of geranyl-resorcinol derivatives that have emerged as particularly promising pharmacological agents among the bioactive secondary metabolites of Hericium erinaceus. They are specifically aromatic meroterpenoid compounds — resorcinol derivatives with enone functionalities — isolated from the fruiting bodies of the edible and medicinal mushroom Hericium erinaceus (commonly known as lion's mane), a fungus biosynthesized endogenously in the mushroom, which grows on decaying broadleaf trees in temperate regions of Asia, Europe, North America, and Oceania.
Hericium erinaceus is known in Japan as Yamabushitake, in China as Hou Tou Gu, and in Europe and the United States as Lion's Mane. These vernacular names derive from the mushroom's distinctive cascading white spines. The hericenones themselves do not carry independent common names beyond their systematic designations (hericenone A, B, C, D, etc.).
A major characteristic compound in H. erinaceus belongs to the class known as hericenones, a meroterpenoid represented by its unique geranyl-resorcinol structure. Hericenones are characterized as low-molecular-weight aromatic compounds, with orsellinic acid serving as a core structural component for various hericenones, hericerins, and erinacines. These compounds are classified as non-cyathane-type meroterpenoids, distinguishing them from the related cyathane diterpenoids known as erinacines, which feature a fused tricarbocyclic skeleton and predominate in fungal mycelia rather than fruiting bodies.
Hericenones, as a class of orsellinic acid-derived meroterpenoids, exhibit unique structural features and biological functions. The core architecture of hericenones typically centers on an aromatic ring system, often manifesting as an isobenzofuranone (phthalide) or isoindolone scaffold, bearing an aldehyde or lactone functionality. Hericenones constitute a class of meroterpenoids characterized by a hybrid biosynthetic origin, combining polyketide-derived aromatic cores — such as methoxyphenol or phthalide moieties — with prenylated terpenoid side chains.
As of the 2026 scoping review in Chemistry & Biodiversity, 24 known natural hericenones and one semisynthetic derivative have been documented, with structural elucidation detailed using characteristic NMR spectroscopy as a systematic identification guide.
The key meroterpenoids found in Hericium erinaceus are broadly categorized into hericenones, primarily isolated from the fruiting bodies, and erinacines, predominantly found in the mycelia. This distinction is fundamental to understanding supplement formulations and research findings, since products derived from dried fruiting body powder are enriched in hericenones, while mycelium-derived products are enriched in erinacines.
Hericium is an edible, wood-rotting fungus of temperate deciduous forests. It is a culinary-medicinal mushroom and has a long history of usage in traditional Chinese medicine as a tonic for stomach disorders, ulcers, and gastrointestinal ailments. H. erinaceus grows on old or dead broadleaf trees and has been used as a medicine for treatment of gastricism in traditional Chinese medicine for more than 1000 years.
Hericium erinaceus has been utilized in traditional Chinese medicine for centuries, where it is described as a tonic to strengthen digestion, enhance vitality, and alleviate stomach discomfort. In this context, the mushroom, known as houtougu or "monkey head mushroom," was prescribed to fortify the spleen, nourish the gut, and address conditions such as chronic gastritis and gastric ulcers by promoting the flow of qi and balancing internal energies.
Similarly, in Japanese Kampo medicine, it is referred to as yamabushitake and employed historically to support gastrointestinal health, including the treatment of stomach ulcers, while also aiding vitality and nervous system function to combat weakness and insomnia. Historical records from China and Japan document its presence in monastic and culinary traditions. Buddhist monks in Japan (Yamabushi, hence the name Yamabushitake) were known to incorporate it, potentially valuing its unique properties within their practices. In traditional Chinese contexts, it has been part of the materia medica, referenced in historical texts for various applications, often prepared as a tea or in soups.
H. erinaceus has been used in traditional folk medicine and medicinal cuisine in China, Korea, and Japan, and evidence has been adduced for a variety of physiological effects, including anti-aging, anti-cancer, anti-gastritis, and anti-metabolic disease properties.
It is important to note that traditional use was of the whole mushroom or its crude preparations — not of isolated hericenones. The scientific identification and isolation of hericenones as distinct chemical entities is entirely a modern achievement.
The initial isolation and characterization of hericenones were reported by Kawagishi and colleagues in 1990. Among the early compounds identified were hericenones C, D, and E, which were recognized for their ability to stimulate nerve growth factor (NGF) synthesis. Hericenones A through H were subsequently identified from the fruiting bodies of Hericium erinaceus.
Hericenones are aromatic compounds isolated from the fruiting body of H. erinaceus. Fresh fruiting bodies of the fungus were extracted with acetone; repeated chromatography of the chloroform-soluble fraction obtained by solvent partitions (chloroform and then ethyl acetate) of the extract with silica gel followed by HPLC with ODS column gave hericenones. Hericenones A, B (Kawagishi et al. 1990), C, D, E (Kawagishi et al. 1991), F, G, H (Kawagishi et al. 1993), hericenes A–C (Alberto et al. 1995) and hericerin (Kimura et al. 1991) were isolated from the mushroom H. erinaceus.
Four new natural compounds named hericenone O, P, Q, and R, two of them reported synthetically (Q and R), together with eleven known compounds were isolated from the fruiting bodies of Hericium erinaceus. The chemical structures of the isolated compounds were elucidated by using NMR analysis and mass spectrometry, as well as comparisons with reported data in the literature.
Hericenone C specifically is a meroterpenoid distinguished by its palmitic acid fatty acid side chain. Its chemical formula is C₃₅H₅₄O₆, and it is classified as an aromatic monoterpenoid.
Hericenones C, D, E, and I are phenols; hericenones A, I, J, H, G, F are ketones; while hericenone B can be categorized as an alkaloid.
The hericenone family encompasses a growing number of structurally related compounds. The most pharmacologically studied are hericenones B, C, D, E, and H. Their differing structural features underlie distinct biological activities.
Hericenones and erinacines are often discussed together, but their precise roles differ. This neuroprotective activity is primarily attributed to two distinct classes of compounds: erinacines from the mycelium, which potently induce the synthesis of neurotrophins, protein growth factors essential for neuronal survival and health, and hericenones from the fruiting body, which subsequently appear to enhance or potentiate neurotrophin-activated signaling pathways.
In a bioassay using mouse astroglial cells, the amounts of NGF secreted into the medium in the presence of erinacines were greater than for hericenones. There is debate as to whether hericenones are active components stimulating biosynthesis of NGF, and recent results have shown that hericenone C, D, and E did not increase NGF mRNA expression at 10–100 μg/ml in 1321N1 cells.
Hericenones, however, have failed to promote NGF activity in 1321N1 human astrocytoma cells or cross the blood–brain barrier in some experimental models, suggesting that they may not be the key compounds responsible for certain neuroprotective effects of this mushroom. This is an area of active scientific debate.
Hericenone E exhibits neurotrophic effects in neuronal cells. This action is associated with the stimulation of NGF synthesis and subsequently increased phosphorylation of the TrkA receptor by NGF, leading to the activation of ERK and Akt signaling pathways. Additionally, hericenone E activates the ERK1/2 and PI3K/Akt cascades independently of the presence of NGF, suggesting that this compound is involved in additional signaling pathways directly regulated by hericenone E.
Preclinical evidence substantiates their ability to enhance neurotrophin levels, particularly Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF), and activate their cognate Trk receptors. Activation of these pathways, including PI3K/AKT/mTOR and MAPK/ERK, converges on transcription factors such as CREB, promoting neuronal survival, neurite outgrowth, and synaptic plasticity. However, the precise molecular mechanisms linking these small molecules to the complex orchestration of neurotrophic gene expression remain incompletely defined.
Nerve growth factor (NGF) has potent biological activities, such as preventing neuronal death and promoting neurite outgrowth, and is essential to maintain and organize neurons functionally. It is assumed that functional deficiency of NGF is related to Alzheimer's disease and plays a part in the etiology of the disease process. However, NGF is a protein and so is unable to cross the blood–brain barrier; it is also easily metabolized by peptidases. This makes small-molecule stimulators of NGF synthesis, such as hericenones and erinacines, of particular pharmacological interest.
Hericenones and erinacines are low-molecular-weight compounds that can cross the blood–brain barrier. However, as noted above, this claim has been contested specifically for hericenones in certain cell-line models.
To test the hypothesis that the neuroprotective activity of hericenone C is the result of the hydrolyzed product rather than the intact compound, it was treated with pancreatic lipase to cleave the fatty acid side chain; the plausible in vivo bioactive form of hericenone C was isolated and investigated. The lipase-derived compound (named deacylhericenone) was found to have higher BDNF mRNA transcription in SH-SY5Y and Caco-2 cells, and increased cell viability in oxidative stress-induced 1321N1 cells, compared to its parent compound. The results of this study provide strong evidence that the neuroprotective activity of hericenone C must, in fact, be attributed to its derivative, deacylhericenone.
Hericenone C inhibits the second phase of formalin-induced nociceptive behavior in mice. LPS-induced NF-κB response element luciferase activity was significantly inhibited by hericenone C, and phosphorylation of p65 — involved in the inflammatory responses of the NF-κB signaling pathway — was significantly reduced by hericenone C. Additionally, in mice, the number of CD11c-positive cells increased in the paw during the peak of the second phase of the formalin test, which decreased upon hericenone C intake.
These findings establish hericenone C as a novel RORα antagonist that alleviates inflammatory pain through inhibition of the RORα-TLR4-NF-κB axis in CD11c⁺ cells. Based on competitive affinity proteomics, researchers identified direct interactions between RORα and hericenone C; functional assays confirmed the role of hericenone C as a RORα antagonist that suppresses RORE-mediated transcriptional activity. Integrated bioinformatics and experimental validation indicated hericenone C-mediated suppression of TLR4 expression via inhibited RORα binding to the TLR4 promoter, which attenuates NF-κB signaling.
Hericenone B had a strong anti-platelet activity and may be a novel compound for antithrombotic therapy possessing a novel mechanism. Hericenone B selectively inhibited collagen-induced platelet aggregation; however, it did not affect the aggregation induced by U46619 (TXA₂ analogue), ADP, thrombin, or adrenaline. Collagen-induced aggregation was inhibited by hericenone B in human platelets, similar to in rabbit platelets. This evidence is entirely preclinical (in vitro and ex vivo).
The chemical composition of H. erinaceus includes polysaccharides, terpenoids (hericenones and erinacines), and phenolic compounds, which exhibit potent antioxidant effects by scavenging reactive oxygen species (ROS) and inducing endogenous antioxidant enzymes. These antioxidant properties have been demonstrated primarily in cell-based and animal models.
Evidence level: Preliminary — limited, small-scale human trials; larger and more rigorous trials needed.
Since the 1990s, several in vitro studies have been conducted, demonstrating the stimulatory effects on the synthesis of nerve growth factor (NGF) by hericenones (C, D, E, H) and erinacines (A–F, H) extracted from H. erinaceus. However, these studies did not provide a clear understanding of the underlying mechanisms of action or how they influence neurite growth.
In terms of human clinical evidence, the most frequently cited study is a double-blind, placebo-controlled trial: A double-blind, parallel-group, placebo-controlled trial was performed on 50- to 80-year-old Japanese men and women diagnosed with mild cognitive impairment to examine the efficacy of oral administration of Yamabushitake (Hericium erinaceus), using a cognitive function scale based on the Revised Hasegawa Dementia Scale. After 2 weeks of preliminary examination, 30 subjects were randomized into two 15-person groups. The subjects of the Yamabushitake group took four 250 mg tablets containing 96% of Yamabushitake dry powder three times a day for 16 weeks. After termination of the intake, the subjects were observed for the next 4 weeks. At weeks 8, 12, and 16 of the trial, the Yamabushitake group showed significantly increased scores on the cognitive function scale compared with the placebo group.
A 2025 systematic review (published in Frontiers in Nutrition) included results from five randomized controlled trials (RCTs), 15 laboratory studies, three pilot clinical trials, one cohort study, one case report, and one computer analysis. The RCTs and pilot clinical trials assessed cognitive improvements in participants with and without dementia. Mini-Mental State Examination scores from one RCT and one pilot clinical trial showed a combined weighted mean increase of 1.17 in the intervention group.
There is still a lack of substantial evidence to support the capacity of H. erinaceus as a therapeutic supplement for humans. Existing randomized controlled trials mainly focus on H. erinaceus's role in improving cognition, dementia, anxiety, and depression. As a dietary supplement, it shows limited effectiveness in clinical trials and is primarily used for temporary improvement in cognitive function and mental clarity. Although erinacines and hericenones derived from its mycelium have shown promising stimulation of NGF, the majority of studies report only limited improvement in neural functional enhancement.
Evidence level: Preliminary — small, short-duration human trials, mostly in specific populations.
Nagano et al. (2010) studied the clinical effects of H. erinaceus on menopause, depression, sleep quality, and indefinite complaints through a structured questionnaire survey in 30 females with an average age of 41.3 years over the period of 4 weeks. Their findings revealed that consumption of cookies containing 0.5 g of fruit body powder alleviated the symptoms of depression, anxiety, frustration, and palpitation. However, the conclusions are less convincing as the study was gender-specific by design as it was related to menopause.
In a separate study, a mean reduction of the depression score of about 30% and above 40% of the anxiety symptoms was reported. The effect of H. erinaceus lasted in the absence of treatment, and these data agree with previous clinical data, which described an improvement in mood disorders after H. erinaceus supplementation.
One study assessed whether a Hericium erinaceus treatment improved depression, anxiety, sleep, and binge eating disorders after 8 weeks of supplementation in subjects affected by overweight or obesity under a low-calorie diet regimen, looking for a possible clinical biomarker through assessment of the serum balance between brain-derived neurotrophic factor (BDNF) and its precursor pro-BDNF. Seventy-seven volunteers affected by overweight or obesity were recruited at the Department of Preventive Medicine, Luigi Devoto Clinic of Work, Obesity Centre, at the IRCCS Foundation Policlinico Hospital of Milan, Italy. Participants in the H. erinaceus intervention group received three capsules containing 80% mycelium extract and 20% fruiting body extract daily for 8 weeks. They found that H. erinaceus significantly reduced depression and anxiety, as well as improving sleep disorders after 8 weeks.
Evidence level: Preliminary — mostly animal models and in vitro data; limited direct clinical evidence specifically for hericenones.
Hericium erinaceus is an edible and medicinal mushroom commonly used in traditional Chinese medicine for centuries. Several studies have highlighted its therapeutic potential for gastrointestinal disorders such as gastritis and inflammatory bowel diseases. In addition, some components of this mushroom appear to possess strong antineoplastic capabilities against gastric and colorectal cancer.
It is reported that H. erinaceus extracts have antimicrobial activities against both antibiotic-resistant and nonresistant pathogenic bacteria, especially Helicobacter pylori, a human gastrointestinal pathogen causing adverse effects including ulcers. Notably, in the gastrointestinal literature, it is largely the polysaccharide and erinacine fractions — rather than hericenones specifically — that have been the primary subjects of study.
Evidence level: Preclinical only — in vitro and ex vivo animal/human platelet experiments; no clinical trials.
Inhibitors of platelet aggregation promise to be preventive or therapeutic agents of various vascular diseases, including myocardial infarction and stroke. In the study examining hericenone B, the authors found that it had a strong anti-platelet activity and it might be a novel compound for antithrombotic therapy possessing a novel mechanism. This research was conducted using washed rabbit and human platelets in vitro; no clinical trials have yet evaluated the cardiovascular effects of isolated hericenones in humans.
Evidence level: Preclinical only — animal models and cell-based studies; no human trials for isolated hericenones.
Research has previously reported that hericenone C alleviated the second phase of formalin-induced nociceptive behaviors. Hericium erinaceus (lion's mane mushroom), a medicinal fungus in traditional Chinese medicine, has been well explored due to its diverse therapeutic properties, including neuroprotective, anti-inflammatory, and immunomodulatory effects. The anti-nociceptive and anti-inflammatory mechanisms described above represent entirely preclinical findings in murine models.
Evidence level: Preclinical only — in vitro cell line studies; no human trials for isolated hericenones.
Hericenone Q showed significant cytotoxic activity against Hep-G2 (hepatocellular carcinoma) with IC50 values of 23.89 μM, and against HCT-116 (colorectal carcinoma) with IC50 values of 65.64 μM. Hericenone L is a new derivative of hericenone that shows cytotoxic activity against the EC109 cell line by the MTT assay. In vitro laboratory studies on cancer and cell apoptosis, focusing on leukemia and gastric cancer cells, found that isolated erinacine A from the mycelium of H. erinaceus inhibited the invasiveness of MKN28 and TSGH 9201 cells and activated caspase pathways. These are in vitro findings and cannot be extrapolated to clinical anticancer outcomes.
Evidence level: Preliminary — limited human and animal data, mostly for whole-mushroom extracts.
H. erinaceus also increased gut microbiota diversity and the abundance of short-chain fatty acid (SCFA)-producing bacteria, thereby reducing inflammation and protecting gut health. These findings apply to whole-mushroom preparations rather than to isolated hericenones specifically.
The established and investigated activities of hericenones include the stimulation of nerve growth factor (NGF), as well as anti-inflammatory, antioxidant, anticancer, antidiabetic, antiplatelet, and anti-obesity activities. The body systems primarily associated with hericenone research are:
Hericium erinaceus is a valuable mushroom known for its strong bioactive properties. It shows promising potential as an excellent neuroprotective agent, capable of stimulating nerve growth factor release, regulating inflammatory processes, reducing oxidative stress, and safeguarding nerve cells from apoptosis. The active compounds in the mushroom, such as erinacines and hericenones, have been the subject of research, providing evidence of their neuroprotective effects.
Hericenones are not commercially available as isolated single compounds in dietary supplement form. Consumer products contain whole fruiting body powder, fruiting body extracts, or mycelium extracts — all of which contain hericenones and/or erinacines as part of their broader phytochemical profile.
The following dosages have been used in published human trials of H. erinaceus preparations:
It is not clear how much of the chemical compounds (hericenones and erinacines) actually reach the brain after taking lion's mane mushroom by mouth. No human clinical studies to date have used isolated, standardized hericenone compounds as the test intervention; all human evidence involves whole or partially purified mushroom preparations.
Further research and standardization processes for dietary supplements focused on H. erinaceus are essential to ensuring effectiveness and safety in protecting the nervous system.
H. erinaceus (lion's mane) is generally recognized as safe and has not been linked to serum enzyme elevations during therapy nor to episodes of clinically apparent liver injury.
Although commonly unreported, potential side effects of H. erinaceus include stomach discomfort, headache, and allergic reactions. Although commonly unreported, potential side effects of H. erinaceus include stomach discomfort, headache, and allergic reactions.
Lion's mane mushroom may cause allergic reactions, which can be serious. Published case reports include an instance of anaphylaxis to lion's mane mushroom (Kobernick, 2022, Annals of Allergy, Asthma & Immunology). Individuals with known mushroom allergies should exercise particular caution.
Because inhibitors of platelet aggregation promise to be preventive or therapeutic agents of various vascular diseases, and since hericenone B was found to have strong anti-platelet activity, there is a theoretical concern regarding additive effects when H. erinaceus preparations are co-administered with anticoagulant or antiplatelet drugs (e.g., warfarin, aspirin, clopidogrel). This interaction has not been evaluated in clinical studies, and the clinical significance is unknown.
Animal studies have indicated that lion's mane mushroom may decrease blood glucose levels and increase serum insulin levels. The clinical significance of this effect in humans has not been established, but it warrants awareness when used alongside antidiabetic medications.
Further research and standardization processes for dietary supplements focused on H. erinaceus are essential to ensuring effectiveness and safety in protecting the nervous system. Most of the available safety data pertain to whole-mushroom preparations at doses used in short-term clinical trials. The safety of isolated hericenone compounds administered to humans has not been studied independently. Long-term safety data, drug interaction studies, and safety data in pregnant and lactating individuals are absent from the published literature.
Hericenones represent a chemically distinct and growing class of meroterpenoid secondary metabolites from Hericium erinaceus. Their most extensively documented biological activities — NGF and BDNF induction, neurite outgrowth promotion, NF-κB pathway modulation, and antiplatelet effects — have been established primarily at the preclinical level through in vitro and animal studies. Extensive research has highlighted the pharmacological properties of H. erinaceus constituents, including neuroprotective, neurotrophic, immunomodulatory, and anticancer activities.
Human clinical data apply to whole-mushroom preparations, not isolated hericenones, and available RCTs are few, small in size, and of short duration. The body of clinical evidence for H. erinaceus includes only five randomized controlled trials and three pilot clinical trials as of 2025 systematic review. The attribution of clinical effects specifically to hericenones — as opposed to erinacines, polysaccharides, or other constituents — cannot currently be made on the basis of available human evidence.
Health conditions that Hericenones may help support.
Hericenones are aromatic compounds isolated from Lion's Mane mushroom (Hericium erinaceus) fruiting bodies shown to stimulate nerve growth factor (NGF) synthesis in neuronal cells. They cross the blood-brain barrier and, along with erinacines, form the mechanistic basis for Lion's Mane's cognitive and neuroprotective effects studied in clinical trials for brain fog and cognitive impairment.
Hericenones are aromatic compounds found in Lion's Mane mushroom fruiting bodies that cross the blood-brain barrier and stimulate NGF (nerve growth factor) synthesis, directly supporting neuroplasticity and cognitive aging. They are the key bioactives underlying human RCT evidence for cognitive improvement in older adults with mild cognitive impairment.
Hericenones are cyathane-type diterpenoids unique to Hericium erinaceus fruiting bodies that stimulate NGF synthesis and support neuronal mitochondrial health. They protect mitochondrial membrane potential, reduce mitochondrial ROS in neuronal models, and are the primary bioactive contributors to Lion's Mane's documented mitochondrial and neuroprotective effects.
Hericenones are bioactive compounds unique to Lion's Mane mushroom fruiting body that stimulate Nerve Growth Factor (NGF) synthesis in the nervous system. Preclinical studies strongly support their neurotrophic role, and they represent the primary active fraction responsible for Lion's Mane's nervous system benefits.
Hericenones are aromatic meroterpenoid compounds isolated exclusively from Hericium erinaceus fruiting bodies that potently stimulate NGF synthesis in vitro. Specific hericenones (C, D, E, H) induce NGF secretion from mouse astroglial cells at measurable concentrations, and their low molecular weight enables blood-brain barrier crossing. They are a principal bioactive fraction underlying Lion's Mane mushroom's neuroprotective and nerve-regenerating properties.
Hericenones are aromatic compounds from the fruiting body of Hericium erinaceus (Lion's Mane) that cross the blood-brain barrier and directly stimulate NGF synthesis in astrocytes and neuroblastoma cells. Since the 1990s, multiple in vitro studies (PubMed) have confirmed their NGF-inducing capacity, making them primary agents for neuroplasticity support.
Body systems that Hericenones may help support.
Go back